Merck's Oral Lipfendra: A Landmark Approval Clouded by Critical Cardiovascular Outcomes Data Gap

Merck's Oral PCSK9 Inhibitor Lipfendra Receives FDA Approval

Merck has received FDA approval for enlicitide, marketed as Lipfendra, making it the first once-daily oral PCSK9 inhibitor for adults with high LDL cholesterol. This approval, supported by Phase 3 CORALreef trials, positions Lipfendra as a significant new option, offering a non-injectable alternative to existing treatments. The drug demonstrated a placebo-adjusted LDL cholesterol reduction of 59% in patients with heterozygous familial hypercholesterolemia (HeFH) and 56% in adults with hypercholesterolemia. Approved under the FDA’s Commissioner’s National Priority Voucher (CNPV) program, Lipfendra is expected to reach peak sales of $5 billion by 2034 and will be launched at a competitive price of $315 per month.

• Lipfendra (enlicitide) marks a significant advancement as the first FDA-approved once-daily oral PCSK9 inhibitor, providing a more accessible treatment option for adults with high LDL cholesterol compared to currently available injectable therapies like Repatha, Praluent, and Leqvio. This approval was expedited through the FDA’s Commissioner’s National Priority Voucher (CNPV) program, highlighting its alignment with U.S. government priorities.
• Clinical trials from the CORALreef program demonstrated strong efficacy, with Lipfendra achieving a placebo-adjusted LDL cholesterol reduction of 59% at 24 weeks in HeFH patients and 56% in adults with hypercholesterolemia. The drug's safety profile was comparable to placebo for non-HeFH patients, and notably, its label carries zero contraindications or hypersensitivity warnings, distinguishing it from existing injectable PCSK9 inhibitors.
• Merck is launching Lipfendra at $315 per month, a meaningful discount compared to injectable PCSK9 inhibitors which range from $500–$600. Analysts project peak sales of approximately $5 billion by 2034, reflecting strong market potential due to its oral formulation, clean label, and competitive pricing, despite ongoing development of other oral PCSK9 candidates by competitors like AstraZeneca.

Lipfendra's Arrival: Evolving the Hypercholesterolemia Landscape

Recent data reveals that while the hypercholesterolemia treatment landscape is evolving, traditional approaches still dominate. In 2021, statin monotherapy accounted for 91.2% of lipid-lowering drug prescriptions in Germany, a figure that underscores its foundational role. Despite a significant 424% increase in the daily doses of ezetimibe monotherapy prescribed between 2012 and 2021, its use as a fixed-dose combination (FDC) with statins saw only a minor 29% increase, remaining stable at approximately 3% of all statin prescriptions. This indicates a slow adoption of combination strategies in routine practice. Even among high and very high-risk patients, 2019 data showed that while many received treatment, it was primarily moderate-intensity statin monotherapy (59.9%), with combination therapy used in a minority of cases. Furthermore, treatment adherence presents a major challenge, with over half of patients (56.6%) pausing or discontinuing therapy over time.

Clinical evidence increasingly supports a shift towards more intensive and combination therapies to achieve stringent LDL-C goals. The ROSE-CH trial, for instance, demonstrated the clear superiority of a rosuvastatin/ezetimibe FDC over rosuvastatin monotherapy. The 10/10 mg combination achieved a 51.48% mean reduction in LDL-C from baseline, compared to 42.47% for rosuvastatin 10 mg alone (P<0.001), leading to significantly higher target achievement rates in patients with very high atherosclerotic cardiovascular disease (ASCVD) risk. Beyond established combinations, the therapeutic arsenal has expanded with the approval of novel agents, including PCSK9 modulators, ATP-citrate lyase inhibitors like bempedoic acid, and ANGPTL3 inhibitors. However, despite their proven efficacy, these advanced medications remain broadly underutilized in global clinical practice.

Despite the availability of more effective treatments, a substantial gap persists between guideline recommendations and real-world outcomes. Data from 2019-2022 shows that while LDL-C target achievement is improving, it remains suboptimal; among Italian patients with type 2 diabetes at very high risk, the proportion reaching the <55 mg/dL target only increased from 16.3% to 23.6%. Modeling studies project that full implementation of current US and EU guidelines could achieve an additional median LDL-C reduction of 37–49 mg/dL, translating to a potential 21-27% relative reduction in major cardiovascular events. The current disparity is stark, with US data showing actual use of ezetimibe and PCSK9 inhibitors at just 4% and 0% respectively, compared to eligibility rates as high as 74% and 53%. This highlights a critical, persistent unmet need for optimizing lipid-lowering strategies in high-risk patients.

CORALreef Program: Efficacy and Safety of Oral Lipfendra

Recent research in hypercholesterolemia highlights a diverse and expanding landscape of therapeutic strategies, ranging from novel drug classes to the refined application of established therapies. Data from late-stage trials, real-world studies, and comprehensive meta-analyses inform the evolving standard of care by evaluating efficacy and safety across various patient populations, including those with comorbidities like type 1 diabetes or metabolic dysfunction-associated steatotic liver disease (MASLD).

• PCSK9-Targeting Agent Comparison: A 2026 real-world retrospective study (n=198) compared the siRNA agent inclisiran with the monoclonal antibodies evolocumab and alirocumab over 180 days. All three agents demonstrated robust and statistically significant reductions in LDL-C from baseline (p<0.001) with no significant differences between them. Inclisiran showed a numerical, though not statistically significant, advantage in apolipoprotein B (apoB) reduction and had the highest treatment persistence rate (69.7% vs. 56.1% for evolocumab and 50.0% for alirocumab), with all agents being well-tolerated.

• CETP Inhibitor Obicetrapib Efficacy: A 2025 meta-analysis of nine randomized controlled trials (n=3,516) established the lipid-modifying efficacy of the selective cholesteryl ester transfer protein (CETP) inhibitor, obicetrapib. Compared to placebo, obicetrapib delivered significant reductions in LDL-C (mean difference: -37.45%), apolipoprotein B (-24.63%), non-HDL-C (-30.96%), triglycerides (-7.5%), and lipoprotein(a) (-40.85%). The agent also produced a substantial increase in HDL-C levels (mean difference: 150.06%) and was not associated with an increased risk of adverse events.

• Statin Applications in Specific Populations: The role of statins is being clarified in distinct patient cohorts. A 2-year RCT in adolescents (ages 10-19) with combined dyslipidemia of overweight/obesity found that pitavastatin calcium 4 mg/d significantly reduced LDL-C compared to placebo (p<0.001) without significant differences in safety events. A 2025 meta-analysis focusing on primary prevention in patients with type 1 diabetes determined that statin use was associated with a significant reduction in the risk of major adverse cardiovascular events (MACE) (pooled HR: 0.77) and a mean LDL-C reduction of 30.3 mg/dL.

• Implementation of Nonstatin Therapies: A 2025 global systematic review of 21 studies investigated strategies to improve the use of nonstatin add-on lipid-lowering therapies (LLTs). The review concluded that prescriber-driven strategies, pharmacist-led interventions (e.g., motivational interviews), and multidisciplinary healthcare provider approaches all effectively enhanced the uptake of optimized, guideline-directed LLTs, leading to improved LDL-C goal attainment and better patient adherence. Key barriers identified included high costs and patient refusal, while reduced skepticism and supportive clinical environments acted as enablers.

Lipfendra's Competitive Edge in Hypercholesterolemia Treatment

Recent clinical trials are evaluating novel therapeutic mechanisms and combination strategies, often demonstrating superior efficacy compared to standard-of-care monotherapies for hypercholesterolemia. Data from studies on CETP inhibitors, PCSK9 inhibitors, and various statin/ezetimibe combinations show significant improvements in lipid-lowering capabilities and patient outcomes. The following table summarizes key comparative findings from published literature.